{"type":"trials","record":{"id":41876,"source_id":"clinicaltrials-gov","external_id":"NCT05461339","title":"TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration","brief_summary":"This study is a randomized, multi-center, double blind, Lucentis controlled non-inferiority study in neovascular age-related macular degeneration patients. The objective of this study is to compare the efficacy and safety of TAB014 and ranibizumab (Lucentis).","overall_status":"Active Not Recruiting","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"BioDlink Biopharm Co., Ltd.","enrollment":488,"countries":["China"],"start_date":"2022-06-28","completion_date":"2025-02-01","last_update_date":"2025-01-07","source_url":"https://clinicaltrials.gov/study/NCT05461339","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"nAMD","age_range":"50 Years to 90 Years","comparator":"Ranibizumb","organization":"BioDlink Biopharm Co., Ltd.","interventions":["TAB014 Monoclonal Antibody Injection","Ranibizumab Injection [Lucentis]"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Evaluate the change in BCVA of the study eye from TAB014 and ranibizumab treatment groups. — At week 52","Evaluate the change in BCVA of the study eye — At week 12, 24 and 36","Evaluate the proportion of subjects with an increase in BCVA of >5, >10, and >15 in the study eye — At week 12, 24 and…","Evaluate the proportion of subjects with a BCVA loss of <5, <10, < 15 letters in the study eye — At week 12, 24 and 52","Change in central subfield thickness（CST) in the study eye — At week 12, 24, 36 and 52","Change in Choroidal Neovascularization (CNV) area of study eye — At week 12, 24 and 52"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","TAB014 Monoclonal Antibody Injection","Ranibizumab Injection [Lucentis]"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05461339","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-06-28 to 2025-02-01","comparator":"Ranibizumb","confidence":"structured-source","population":"ALL · 50 Years to 90 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.885Z","intervention":["TAB014 Monoclonal Antibody Injection","Ranibizumab Injection [Lucentis]"],"participants":488,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Evaluate the change in BCVA of the study eye from TAB014 and ranibizumab treatment groups. — At week 52","Evaluate the change in BCVA of the study eye — At week 12, 24 and 36","Evaluate the proportion of subjects with an increase in BCVA of >5, >10, and >15 in the study eye — At week 12, 24 and…","Evaluate the proportion of subjects with a BCVA loss of <5, <10, < 15 letters in the study eye — At week 12, 24 and 52","Change in central subfield thickness（CST) in the study eye — At week 12, 24, 36 and 52","Change in Choroidal Neovascularization (CNV) area of study eye — At week 12, 24 and 52"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41876","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}